Clofazimine-d7

Clofazimine-d7 is intended for use as an internal standard for the quantification of clofazimine by GC- or LC-MS. Clofazimine is an antimycobacterial compound with MICs ranging from 0.03 to 0.12 μg/ml against clinical isolates of M. paratuberculosis.1 It also has activity against 80 isolates of M. fortuitum, M. chelonae, and M. fallax (MICs = ≤0.25-8 μg/ml).2 Clofazimine (25 mg/kg per day) reduces the number of M. tuberculosis-infected cells in the spleen and lungs of mice infected with the multidrug-resistant clinical isolate strain CNL.3 Formulations containing clofazimine have been used for the treatment of leprosy and drug-resistant tuberculosis.4

References
1. Chiodini, R.J. Bactericidal activities of various antimicrobial agents against human and animal isolates of Mycobacterium paratuberculosis. Antimicrob. Agents Chemother. 34(2), 366-367 (1990).
2. Ausina, V., Condom, M.J., Mirelis, B., et al. In vitro activity of clofazimine against rapidly growing nonchromogenic mycobacteria. Antimicrob. Agents Chemother. 29(5), 951-952 (1986).
3. Klemens, S.P., DeStefano, M.S., and Cynamon, M.H. Therapy of multidrug-resistant tuberculosis: Lessons from studies with mice. Antimicrob. Agents Chemother. 37(11), 2344-2347 (1993).
4. Szeto, W., Garcia-Buitrago, M.T., Abbo, L., et al. Clofazimine enteropathy: A rare and underrecognized complication of mycobacterial therapy. Open Forum Infect. Dis. 3(3), ofw004 (2016).